Technology evaluation: Sch-58500, Canji.
作者信息
Barnard D L
机构信息
Institute for Antiviral Research, Utah State University, 5600 Main Hill, Logan, UT 84322, USA.
出版信息
Curr Opin Mol Ther. 2000 Oct;2(5):586-92.
PMID:11249761
Abstract
Sch-58500 is a gene therapy utilizing the p53 gene and is under development by Canji and Schering-Plough for the potential treatment of various types of cancer. It is in phase II/III clinical trials in the US for stage III ovarian cancer [328228,328893], phase II clinical trials for hepatocellular and colorectal cancer metastatic to the liver [273331,324279], and phase I clinical trials for several other types of cancer [282801,284932,328228].
摘要
Zotero 插件